The political economy of AIDS treatment: Intellectual property and the transformation of generic supply

International Studies Quarterly

Volumn 51, Issue 3, 2007, Pages 559-581

  Shadlen, Kenneth C ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING WORLD; INTELLECTUAL PROPERTY RIGHTS; INTERNATIONAL LAW; POLITICAL ECONOMY; PUBLIC HEALTH;

EID: 34548071048     PISSN: 00208833     EISSN: 14682478     Source Type: Journal    
DOI: 10.1111/j.1468-2478.2007.00464.x     Document Type: Article

References (79)

1. Abbott, Frederick M. (2005) The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health. The American Journal of International Law 99 (2): 317-358.
2. d' Adesky, Anne-christine. (2004) Moving Mountains: The Race to Treat Global AIDS. New York: Verso.
3. Attaran, Amir. (2004) How Do Patents and Economic Policies Affect Access to Essential Medicines in Developing Countries? Health Affairs 23 (3): 155-166.
4. Attaran, Amir, and Lee Gillespie -White. (2001) Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa? Journal of the American Medical Association 286 (15): 1886-1892.
5. Baker, Brook K. (2005) India's 2005 Patent Act: Death by Patent or Universal Access to Second- and Future-Generation ARVs? Background Paper, Health GAP. Available at http://www.healthgap.org/press_releases/ 05/091905_HGAP_BP_India_patent_baker.html. (Accessed April 5, 2007).
6. Barnett, Tony, and A lan W hiteside. (2006) AIDS in the Twenty-First Century: Disease and Globalization. 2nd edition. Basingstoke: Palgrave.
7. Basheer, Shamnad. (2005) India's Tryst with TRIPS: The Patents (amendment) Act 2005. Indian Journal of Law and Technology. Vol. 1. Available at http://ssrn.com/abstract=764066. (Accessed April 5, 2007).
8. Berwick, Donald. (2002) 'We all have AIDS': Case for Reducing the Cost of HIV Drugs to Zero. British Medical Journal 324 (7331): 214-216.
9. Bhandari, Bhupesh. (2005) Patent regime? Not the end of the road. Business Standard. 2 February. Available at http://www.rediff.com/money/ 2005/feb/02guest1.htm. (Accessed April 5, 2007).
10. Boelaert, Marleen, Lut Lynen, Wim Van Damme, Robert Colebunders, Eric Goemaere, Anne-Valerie Kaninda, Laura Ciaffi, Maryline Mulemba, Ellen 'Hoen, Bernard Pécoul, Médecins Sans Frontières, Michael J. Selgelid, Udo Schuklenk, Amir Attaran, and Lee Gillespie-White. (2002) Do Patents Prevent Access to Drugs for HIV in Developing Countries? Journal of American Medical Association 287 (7): 809-938.
11. Chaudhuri, Sudip. (2005) The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries. New Delhi: Oxford University Press. (India).
12. CIPR. (2002) Integrating Intellectual Property Rights and Development Policy. London: Commission on Intellectual Property Rights.
13. Cohen, Jillian Clare, and Kristina M. Lybecker. (2005) AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health. The World Economy 28 (2): 211-230.
14. Correa, Carlos. (2000a) Integrating Public Health Concerns into Patent Legislation in the Developing Countries. Geneva: South Centre.
15. Correa, Carlos. (2000b) Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options. London and New York: Zed Books.
16. Drahos, Peter. (1995) Global Property Rights in Information: The Story of TRIPS at the GATT. Prometheus 13 (1): 6-19.
17. Express Pharma Pulse. (2005) Patent Act Will Not Affect Drugs Export: Kamal Nath, January 31. Available at http://www.expresspharmapulse.com/ story.php?&idno=687. (Accessed April 20, 2007).
18. Fink, Carsten. (2001) Patent Protection, Transnational Corporations and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry. Journal of Industry, Company and Trade 1 (1): 101-121.
19. Friedman, Steven, and Shauna Mottiar. (2005) A Rewarding Engagement? The Treatment Action Campaign and the Politics of HIV/AIDS. Politics & Society 33 (4): 511-565.
20. Galvão, Jane. (2002) Access to Antiretroviral Drugs in Brazil. The Lancet 360 (9348): 1862-1865.
21. Gehl Sampath, Padmashree. (2005) Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry. United Nations University-INTECH. Available at http://www.who.int/intellectualproperty/studies/ PadmashreeGehlSampathFinal.pdf. (Accessed April 5, 2007).
22. GFATM. (2005) Purchase Price Report. Geneva: Global Fund Against Aids, Tuberculosis, and Malaria. Available at http://web.theglobalfund.org/prm/ . (Accessed April 5, 2007).
23. Grace, Cheri. (2004) The Effect of Changing Intellectual Property on Pharmaceutical Industry Prospects in India and China: Considerations for Access to Medicines. DFID Health Systems Resource Centre. Available at http://www.dfid.gov.uk/pubs/files/indiachinadomproduce.pdf.
24. Grace, Cheri. (2005) A Briefing Paper for DFID: Update on China and India and Access to Medicines. DFID Health Systems Resource Centre. Available at http://www.dfidhealthrc.org/what_new/ Final%20India%20China%20Report.pdf.
25. Granville, Brigitte, ed. (2002). The Economics of Essential Medicines. London: Royal Institute of International Affairs.
26. Heins, Volker. (2008, forthcoming) Human Rights, Intellectual Property, and the Struggles for Recognition. Human Rights Review 9 (2).
27. 't Hoen, Ellen. (2002) TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to Doha. Chicago Journal of International Law 3 (1): 27-46.
28. Kaplan, Warren, and Richard Laing. (2005) Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. HNP Discussion Paper. Washington, DC: The World Bank.
29. Katrak, Homi. (2004a) Affordable Prices for Essential Medicines for Developing Countries: Some Economic Issues. Development Policy Review 22 (3): 309-320.
30. Katrak, Homi. (2004b) The Indian Pharmaceutical Industry and Consumer Welfare: Prospects under the TRIPS Regime. In The WTO and Developing Countries, edited by H. Katrak and R. Strange. New York: Palgrave/ Macmillan.
31. Keck, M., and K. Sikkink. (1998) Activists Beyond Borders: Advocacy Networks in International Politics. Ithaca: Cornell University Press.
32. Khagram Sanjeev, James Riker, and Kathryn Sikkink, eds. (2002) Reconstructing World Politics: Transnational Social Movements, Networks and Norms. Minneapolis, MN: Univesrity of Minnesota Press.
33. Kovsted, Jens. (2005) Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments. Development Policy Review 23 (4): 465-482.
34. Kumar, Nagesh. (2003) Intellectual Property Rights, Technology and Economic Development: Experiences of Asian Countries. Economic and Political Weekly 38 (3): 209-225.
35. Lanjouw, Jean O. (1998) The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering? NBER Working Paper 6366.
36. L ondon, S imon. (2004) Benevolence and the Bottom Line. Financial Times, July 14. Available at http://www.ft.com. (Accessed April 20, 2007).
37. Lucchini, Stéphane, Boubou Cisse, Ségolène Duran, Marie de Cenival, Caroline Comiti, Marion Gaudry, and Jean-Paul Moatti. (2003) Decrease in Prices of Antiretroviral Drugs for Developing Countries: From Political 'Philanthropy' to Regulated Markets. In Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges, edited by J. Moatti, B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin, and Y. Flori. Paris: ANRS.
38. Matthews, Duncan. (2004) WTO Decision on Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: A Solution to the Access to Essential Medicines Problem? Journal of International Economic Law 7 (1): 73-107.
39. Matthews, Duncan. (2006) From the August 30, 2003 WTO Decision to the December 6, 2005 Agreement on an Amendment to TRIPS: Improving Access to Medicines in Developing Countries? Intellectual Property Quarterly 10 (1): 91-130.
40. May, Christopher. (2002) Unacceptable Costs: The Consequences of Making Knowledge Property in a Global Society. Global Society 16 (2): 123-144.
41. Moatti, Jean -Paul, Benjamin Coriat, Yves Souteyrand, Tony Barnett, Jérôme Dumoulin, and Yves-Antoine Flori, ed. (2003) Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges. Paris: ANRS.
42. MSF. (2005) Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries. 8th edition. Available at http://www.doctorswithoutborders.org/publications/reports/2005/ untanglingthewebv8.pdf. (Accessed April 5, 2007).
43. MSF-WHO-UNAIDS. (2003) Surmounting Challenges: Procurement of Antiretroviral Medicines in Low- and Middle-Income Countries. The Experience of Médecins Sans Frontières. Available at http://www.accessmed-msf.org/documents/procurementreport.pdf. (Accessed April 5, 2007).
44. Mukherjee, J.S., P. E. Farmer, D. Niyizonkiza, L. Mc Corkle, C. Vanderwarker, P. T eixeira, and J.Y. Kim. (2003) Tackling HIV in Resource Poor Countries. British Medical Journal 327 (7423): 1104-1106.
45. Nattrass, Nicoli, and Nathan Geffen. (2005) The Impact of Reduced Drug Prices on the Cost-Effectiveness of HAART in South Africa. African Journal of AIDS Research 4 (1): 65-67.
46. Nogués, Julio. (1993) Cost and Benefits of Introducing Patent Protection for Pharmaceutical Drugs in Developing Countries. The Developing Economies 31 (1): 24-53.
47. Orsi, Fabienne, Lia Hasenclever, Beatriz Fialho, Paulo Tigre, and Benjamin Coriat. (2003) Intellectual Property Rights, Anti-AIDS Policy and Generic Drugs: Lessons from the Brazilian Public Health Program. In Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges, edited by J. Moatti, B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin, and Y. Flori. Paris: ANRS.
48. Pierson, Paul. (2004) Politics in Time: History, Institutions, and Social Analysis. Princeton: Princeton University Press.
49. Reichman, Jerome H., and Catherine Hasenzahl. (2003) Non-voluntary Licensing of Patented Inventions: Historical Perspective, Legal Framework under TRIPS, and an Overview of the Practice in Canada and the USA. UNCTAD-ICTSD Project on IPRs and Sustainable Development, Issue Paper No. 5.
50. Roffe, Pedro, Geoff Tansey, and David Vivas-Eugui, ed. (2006) Negotiating Health: Intellectual Property and Access to Medicines. London: Earthscan.
51. Schrank, Andrew. (2005) Conquering, Comprador, or Competitive: The National Bourgeoisie in the Developing World. In New Directions in the Sociology of Global Development, edited by F. Buttel and P. McMichael. Amsterdam: JAI/Elsevier.
52. Schurman, Rachel. (2004) Fighting 'Frankenfoods': Industry Opportunity Structures and the Efficacy of the Anti-Biotech Movement in Western Europe. Social Problems 51 (2): 243-268.
53. Schwartländer, B., J. Stover, N. Walker, L. Bollinger, J.P. Gutierrez, W. Mc Greevey, M. Opuni, S. Forsythe, L.Kumaranayake, C. Watts, and S. Bertozzi. (2001) Resource Needs for HIV/AIDS. Science 292 (5526): 2434-2436.
54. Seckinelgin, Hakan. (2006) The Multiple Worlds of NGOs and HIV/AIDS: Rethinking NGOs and their Agency. Journal of International Development 18 (5): 715-727.
55. Sell, Susan K. (2002) TRIPS and the Access to Medicines Campaign. Wisconsin International Law Journal 20 (3): 481-522.
56. Sell, Susan K. (2003) Private Power, Public Law: The Globalization of Intellectual Property Rights. London: Cambridge University Press.
57. Sell, Susan K. (2006) Books, Drugs and Seeds: The Politics of Access. Paper presented at the annual meeting of the International Studies Association, San Diego, CA (March).
58. Sever, Patrice, Paul Leger, Macarthur Charles, Francine Noel, Gerry Bonhomme, Gyrlande Bois, Erik George, Stefan Kenel-Pierre, Peter F. Wright, Roy Gulick, Warren D. Johnson, Jean William Pape, and Daniel W. Fitzgerald. (2005) Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti. New England Journal of Medicine 353 (22): 2325-2334.
59. Shadlen, Kenneth C. (2004a) Patents and Pills, Power and Procedure: The North-South Politics of Public Health in the WTO. Studies in Comparative International Development 39 (3): 76-108.
60. Shadlen, Kenneth C. (2004b) Challenges to Treatment: The Price-Infrastructure Trap and Access to Medicines. Journal of International Development 16 (8): 1169-1180.
61. Singh, Pragya, and Dev Chatterjee. (2004) Pharma's in the Den. The Sunday Express, December 19. Available at http://www.indianexpress.com/ full_story.php?content_id=61096. (Accessed April 20, 2007).
62. Smith, Raymond, and Patricia Siplon. (2006) Drugs into Bodies: Global AIDS Treatment Activism. Westport: Praeger.
63. Tarrow, Sidney. (1994) Power in Motion: Social Movements and Contentious Politics. Cambridge: Cambridge University Press.
64. Tayler Yolanda, ed. (2004) Battling HIV/AIDS: A Decision Maker's Guide to the Procurement of Medicines and Related Supplies. Washington, DC: The World Bank.
65. UNAIDS. (2006) Report on the Global AIDS Epidemic: A UNAIDS 10th Anniversary Special Edition. Geneva: UNAIDS.
66. Wainberg, Mark A. (2005) Generic HIV Drugs: Enlightened Policy for Global Health. New England Journal of Medicine 352 (8): 747-750.
67. Wall Street Journal. (2003) Brazil to Stir Up AIDS-Drug Battle: Nation to Authorize Imports of Generics, Citing the Cost of Big Companies' Drugs. 5 September.
68. Watal, Jayashree. (2000) Intellectual Property Rights in the World Trade Organization: The Way Forward for Developing Countries. New Delhi: Oxford University Press (India).
69. WHO. (1998) Globalization and Access to Drugs: Perspectives on the WTO/ TRIPS Agreement. Health Economics and Drugs, DAP Series No. 7 (Revised), WHO/DAP.98.9. Available at http://whqlibdoc.who.int/hq/1998/ WHO_DAP_98.9_revised.pdf. (Accessed April 5, 2007).
70. WHO. (2001) Globalization, Patents and Drugs: An Annotated Bibliography. Health Economics and Drugs, EDM Series No. 10. WHO/EDM/PAR/2001.1.
71. WHO. (2002) Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines. Health Economics and Drugs, EDM Series No. 11, WHO/EDM/PAR/2002.1.
72. WHO. (2003) Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2003 Revision. Geneva: World Health Organization. Available at http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. (Accessed April 5, 2007).
73. WHO. (2004) Manufacture of Antiretrovirals in Developing Countries and Challenges for the Future. EB114/15. Available at http://www.who.int/gb/ ebwha/pdf_files/EB114/B114_15-en.pdf. (Accessed April 5, 2007).
74. WHO. (2005) Intellectual Property Protection: Impact on Public Health. WHO Drug Information 19 (3): 236-241.
75. WHO. (2006) Access to HIV/AIDS Drugs and Diagnostics of Acceptable Quality. Procurement, Quality and Sourcing Project. http://mednet3.who.int/prequal. (Accessed April 5, 2007).
76. WHO/UNAIDS. (2006) Progress on Global Access to HIV Antiretroviral Therapy: A Report on 3 by 5 and Beyond. Geneva: World Health Organization.
77. World Bank. (2004) HIV/AIDS Medicines and Related Supplies: Contemporary Context and Procurement. Technical Guide. Washington, DC: The World Bank.
78. WTO. (2003a) Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: Decision of the General Council of 30 August 2003. WT/L/540. Available at http://www.wto.org/english/ tratop_e/trips_e/implem_para6_e.htm. (Accessed April 5, 2007).
79. WTO. (2003b) The General Council Chairperson's Statement. Available at http://www.wto.org/english/news_e/news03_e/trips_stat_28aug03_e.htm. (Accessed April 5, 2007).